2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Bacterial, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4471 Skilled nursing facility utilization and post-acute outcomes among Medicare beneficiaries with hemophilia

Stacey Fedewa, PhD, Mohamad Ali Tfaily, MD MS2, Tinatin Muradashvili, MD3, Ana Gabriela Antun, MD4, Stefanie M. Digiandomenico, MD MS5, Christine Kempton, MD, MSc6
1 Emory University, Atlanta, Georgia, United States
2 Emory University, Atlanta, Georgia, United States
3 Emory University, Atlanta, Georgia, United States
4 Emory University, Atlanta, Georgia, United States
5 Emory University, Atlanta, Georgia, United States
6 Emory University, Atlanta, Georgia, United States

Introduction: Advances in hemophilia care have increased life expectancy, resulting in a growing cohort of older adults with age-related comorbidities and increased need for post-acute care. Skilled nursing facilities (SNFs) may be reluctant to accept people with hemophilia (PwH) because of reimbursement challenges, concerns about bleeding complications, and facilities' limited experience with hemophilia-specific care, including factor administration. However, population-level differences in SNF utilization and outcomes in PwH have not been quantified. This study aims to compare SNF utilization and post-SNF outcomes among PwH with matched individuals without hemophilia. 

Methods: PwH who were hospitalized for ≥3 days (meeting Medicare SNF eligibility criteria) were identified from Medicare claims data (2000-2020) using a validated algorithm and diagnostic codes.  Among PwH, multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CI) for SNF admissions. Conditional logistic regression was used to compare SNF admission between PwH and the general Medicare population, matched by age, sex, and hospitalization year. Among those with a SNF admission, length of stay (LOS) was estimated with generalized linear models with a gamma distribution, and 30-day hospital readmission was analyzed with logistic regression models. 

Results: Among 1,713 PwH who met SNF-eligibility criteria, the mean age at index hospitalization was 63.1 years, 83.4% were male, and 60.8% were ≥65 years. Overall, 21.7% of PwH eligible were admitted to an SNF. Among PwH, the aOR of SNF admission was significantly greater in females vs males (aOR=1.70, 95%CI 1.21, 2.39) and those with a more recent hospital index year. Compared with matched controls, PwH had 23% lower odds of SNF admission (aOR= 0.77, 95% CI 0.59, 0.89).  The average SNF LOS in PwH was 9.7 days, and 24.8% were readmitted within 30 days of SNF discharge; neither was significantly different from the general population (LOS β=-.07, standard error=0.14; p-value=.60; readmission aOR = 1.06, 95%CI 0.82, 1.37).  

Conclusion: Among Medicare beneficiaries, approximately 1 in 5 PwH had an SNF admission. Compared with the general population, PwH had lower SNF admissions despite comparable post-SNF outcomes. These findings suggest that lower SNF utilization may reflect potential differences to SNF admission rather than differences in post-acute care needs or outcomes. As a pre-policy assessment, this study established an important baseline for evaluating whether the 2021 SNF Access Act, which increased Medicare reimbursement to SNFs for factor-replacing therapies, reduces barriers to SNF admissions for PwH.  

Stacey Fedewa, PhD: No relevant conflicts of interest to declare.